Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.

N Engl J Med. 2002 Aug 15;347(7):472-80.

2.

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Demetri GD.

Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26. Review.

PMID:
11740803
3.

[Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].

Wan DS, Wu XJ, Pan ZZ, Zhou ZW, Chen G, Li LR, Lu ZH, Ding PR.

Zhonghua Yi Xue Za Zhi. 2006 Nov 21;86(43):3064-7. Chinese.

PMID:
17288838
4.

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.

Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23.

PMID:
19307738
5.

[Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].

Shen L, Jin ML.

Zhonghua Zhong Liu Za Zhi. 2004 Nov;26(11):697-9. Chinese.

PMID:
15777512
6.

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R.

Clin Cancer Res. 2002 Oct;8(10):3034-8.

7.

Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.

Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC.

Surgery. 2003 Oct;134(4):656-65; discussion 665-6.

PMID:
14605627
8.

A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients.

Sawaki A, Yamao K, Nakamura T, Suzuki T, Okubo K, Hara K, Kawai H, Yamamura Y, Ito S, Mochiduki Y, Ohno R.

J Gastroenterol. 2004;39(4):329-33.

PMID:
15168243
9.

Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.

Bauer S, Hagen V, Pielken HJ, Bojko P, Seeber S, Schütte J.

Anticancer Drugs. 2002 Sep;13(8):847-9.

PMID:
12394270
10.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC.

J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452.

PMID:
18235122
11.

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.

Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT.

Cancer. 2005 May 15;103(10):2128-31.

12.

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS.

Eur J Cancer. 2003 Sep;39(14):2006-11.

PMID:
12957454
13.

Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.

Sawaki A, Yamao K.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S44-9. Review.

PMID:
15309514
14.

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.

Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL.

J Clin Oncol. 2005 Jan 20;23(3):585-90.

PMID:
15659505
15.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA.

J Clin Oncol. 2003 Dec 1;21(23):4342-9.

PMID:
14645423
16.

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Cohen MH, Farrell A, Justice R, Pazdur R.

Oncologist. 2009 Feb;14(2):174-80. doi: 10.1634/theoncologist.2008-0255. Epub 2009 Feb 4.

17.

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.

Croom KF, Perry CM.

Drugs. 2003;63(5):513-22; discussion 523-4. Review.

PMID:
12600228
18.

Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.

Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW.

Ann Surg Oncol. 2007 Jan;14(1):14-24.

PMID:
17072676
19.

[Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb].

Vrbanec D, Petricević B, Majerović M, Stern-Padovan R, Belev B, Skegro M, Herceg D, Plestina S, Dedić-Plavetić N, Jakić-Razumović J.

Lijec Vjesn. 2006 May-Jun;128(5-6):161-6. Croatian.

PMID:
16910417
20.

Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.

Kobayashi K, Szklaruk J, Trent JC, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, Hicks ME, Gupta S.

Am J Clin Oncol. 2009 Dec;32(6):574-81. doi: 10.1097/COC.0b013e31819cca35.

PMID:
19636238

Supplemental Content

Support Center